Disease by Infectious Agent

Categories: Infectious diseases

Aliases & Classifications for Disease by Infectious Agent

MalaCards integrated aliases for Disease by Infectious Agent:

Name: Disease by Infectious Agent 12 15
Infectious Disease 12 54 17
Infectious Diseases 42 15


External Ids:

Disease Ontology 12 DOID:0050117
ICD9CM 34 079.0
ICD10 32 B98
UMLS 70 C0001485

Summaries for Disease by Infectious Agent

MedlinePlus : 42 Germs, or microbes, are found everywhere - in the air, soil, and water. There are also germs on your skin and in your body. Many of them are harmless, and some can even be helpful. But some of them can make you sick. Infectious diseases are diseases that are caused by germs. There are many different ways that you can get an infectious disease: Through direct contact with a person who is sick. This includes kissing, touching, sneezing, coughing, and sexual contact. Pregnant mothers can also pass some germs along to their babies. Through indirect contact, when you touch something that has germs on it. For example, you could get germs if someone who is sick touched a door handle, and then you touch it. Through insect or animal bites Through contaminated food, water, soil, or plants There are four main kinds of germs: Bacteria - one-celled germs that multiply quickly. They may give off toxins, which are harmful chemicals that can make you sick. Strep throat and urinary tract infections are common bacterial infections. Viruses - tiny capsules that contain genetic material. They invade your cells so that they can multiply. This can kill, damage, or change the cells and make you sick. Viral infections include HIV/AIDS and the common cold. Fungi - primitive plant-like organisms such as mushrooms, mold, mildew, and yeasts. Athlete's foot is a common fungal infection. Parasites - animals or plants that survive by living on or in other living things. Malaria is an infection caused by a parasite. Infectious diseases can cause many different symptoms. Some are so mild that you may not even notice any symptoms, while others can be life-threatening. There are treatments for some infectious diseases, but for others, such as some viruses, you can only treat your symptoms. You can take steps to prevent many infectious diseases: Get vaccinated Wash your hands often Pay attention to food safety Avoid contact with wild animals Practice safe sex Don't share items such as toothbrushes, combs, and straws

MalaCards based summary : Disease by Infectious Agent, also known as infectious disease, is related to parasitic protozoa infectious disease and coronavirus infectious disease. An important gene associated with Disease by Infectious Agent is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Ceftriaxone and Colistin have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and t cells, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 A disease that is the consequence of the presence of pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, and aberrant proteins known as prions.

Related Diseases for Disease by Infectious Agent

Diseases related to Disease by Infectious Agent via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1460)
# Related Disease Score Top Affiliating Genes
1 parasitic protozoa infectious disease 33.1 TLR9 TLR7 TLR4 TLR2 SERPINA3 IL18
2 coronavirus infectious disease 33.1 SERPINA3 IL10 H2AC18 CD209 CCR6
3 chlamydia 33.1 TLR4 TLR2 MBL2 IL18 IL17A IL10
4 human immunodeficiency virus infectious disease 33.0 TLR9 TLR7 SERPINA3 MBL2 IL10 IFNG
5 shigellosis 33.0 TLR4 IL18 IL10
6 commensal bacterial infectious disease 33.0 TLR4 TLR2 SERPINA3 IL17A IL10 IFNG
7 anogenital venereal wart 33.0 TLR9 TLR7 TLR4 H2AC18 CCR6
8 parasitic helminthiasis infectious disease 33.0 TLR4 TLR2 SERPINA3 MIR21 IL17A IL10
9 primary bacterial infectious disease 33.0 TLR9 TLR4 TLR2 SLC11A1 SERPINA3 MIR21
10 leishmaniasis 32.9 TLR9 TLR4 TLR2 SLC11A1 IL17A IL10
11 cystic echinococcosis 32.9 TLR4 TLR2 IL17A IL10 IFNG
12 measles 32.8 TLR9 TLR7 TLR4 TLR2 IFNG CD209
13 fungal infectious disease 32.8 TLR4 TLR2 IL17A IL10 IFNG ICOSLG
14 viral infectious disease 32.8 TLR9 TLR7 TLR4 TLR2 MIR122 IL18
15 melioidosis 32.8 TLR4 TLR2 IL18 IL10 IFNG
16 lyme disease 32.7 TLR9 TLR7 TLR2 IL17A
17 bacterial infectious disease 32.7 TLR9 TLR4 TLR2 SLC11A1 SERPINA3 MIR155
18 malaria 32.7 TLR9 TLR4 TLR2 SERPINA3 MBL2 IL18
19 buruli ulcer 32.6 SLC11A1 IL10 IFNG
20 brucellosis 32.6 TLR4 SLC11A1 IL18 IL17A IL10 IFNG
21 plague 32.6 TLR4 TLR2 IL10 H2AC18
22 mycobacterium tuberculosis 1 32.6 TLR9 TLR4 TLR2 SLC11A1 SERPINA3 MIR21
23 q fever 32.6 TLR4 TLR2 SLC11A1 MBL2 IL10 IFNG
24 tularemia 32.5 TLR4 TLR2 SLC11A1 MBL2 IL17A CCR6
25 hepatitis b 32.5 TLR4 TLR2 MIR21 MBL2 IFNGR1 IFNG
26 intestinal schistosomiasis 32.5 IL17A IL10 ICOSLG CCR6
27 lymphocytic choriomeningitis 32.5 TLR2 ICOSLG CD209
28 syphilis 32.5 SERPINA3 IL17A IFNG CD209 CCR6
29 trachoma 32.5 SERPINA3 MBL2 IL17A IL10
30 hepatitis a 32.5 TLR4 IL10 IFNG
31 cysticercosis 32.5 TLR4 IL18 IL10
32 urinary schistosomiasis 32.5 IL10 IFNG ICOSLG
33 chickenpox 32.5 MIR122 IL10 IFNG ICOSLG CCR6
34 dengue disease 32.4 MBL2 IL10 IFNG H2AC18 CD209
35 typhoid fever 32.4 TLR4 SLC11A1 IFNGR1 IFNG CCR6
36 leptospirosis 32.4 TLR2 IL18 IL10 IFNG
37 leprosy 3 32.4 TLR9 TLR4 TLR2 SLC11A1 IL17A IL10
38 salmonellosis 32.4 TLR4 TLR2 SLC11A1 IL18 IL17A IL10
39 renal infectious disease 32.4 TLR2 IL18
40 toxic shock syndrome 32.4 TLR4 TLR2 IL10 IFNG
41 herpangina 32.4 TLR9 TLR7 TLR4 TLR2 IL10 IFNG
42 schistosomiasis 32.4 IL17A IL10 IFNGR1 IFNG
43 hand, foot and mouth disease 32.4 TLR7 TLR4 IL10 IFNG CD209
44 immune deficiency disease 32.4 TLR9 TLR2 SERPINA3 MIR21 MIR155 MBL2
45 pulmonary tuberculosis 32.4 TLR2 SLC11A1 MBL2 IL18 IL10 IFNGR1
46 herpes zoster 32.3 TLR2 IL10 IFNG ICOSLG CCR6
47 filariasis 32.3 TLR9 TLR4 TLR2 IL10 IFNG
48 echinococcosis 32.3 TLR4 TLR2 IL17A IL10 IFNG
49 dysentery 32.3 IL10 H2AC18 CCR6
50 trypanosomiasis 32.3 TLR9 IL18 IL10 IFNG H2AC18

Graphical network of the top 20 diseases related to Disease by Infectious Agent:

Diseases related to Disease by Infectious Agent

Symptoms & Phenotypes for Disease by Infectious Agent

MGI Mouse Phenotypes related to Disease by Infectious Agent:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CCR6 CD209 IFNG IFNGR1 IL10 IL17A
2 digestive/alimentary MP:0005381 9.97 IFNG IFNGR1 IL10 IL17A IL18 SLC11A1
3 immune system MP:0005387 9.93 CCR6 IFNG IFNGR1 IL10 IL17A IL18
4 integument MP:0010771 9.61 IFNG IFNGR1 IL10 IL17A IL18 SERPINA3
5 renal/urinary system MP:0005367 9.23 IFNG IFNGR1 IL17A MBL2 TLR2 TLR4

Drugs & Therapeutics for Disease by Infectious Agent

Drugs for Disease by Infectious Agent (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
Cefoxitin Approved Phase 4 35607-66-0 441199
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
Tazobactam Approved Phase 4 89786-04-9 123630
Piperacillin Approved Phase 4 66258-76-2 43672
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
Cloxacillin Approved, Investigational, Vet_approved Phase 4 61-72-3 6098
Ethambutol Approved Phase 4 74-55-5 3279 14052
Vancomycin Approved Phase 4 1404-90-6 14969 441141
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
Dalbavancin Approved, Investigational Phase 4 171500-79-1, 91097-81-3 122186
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
Lopinavir Approved Phase 4 192725-17-0 92727
Hydroxychloroquine Approved Phase 4 118-42-3 3652
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
23 Lactams Phase 4
24 beta-Lactams Phase 4
25 Cephalosporins Phase 4
26 Piperacillin, Tazobactam Drug Combination Phase 4
27 Acidophilus Phase 4
28 Opiate Alkaloids Phase 4
29 Antibiotics, Antitubercular Phase 4
30 Anti-Bacterial Agents Phase 4
31 methicillin Phase 4
32 Coagulase Phase 4
33 beta-Lactamase Inhibitors Phase 4
34 penicillins Phase 4
35 Clavulanic Acids Phase 4
36 Interleukin-2 Phase 4
37 Amoxicillin-Potassium Clavulanate Combination Phase 4
38 Antiviral Agents Phase 4
39 Cytochrome P-450 Enzyme Inhibitors Phase 4
40 Analgesics, Non-Narcotic Phase 4
41 Analgesics Phase 4
42 Anti-Retroviral Agents Phase 4
43 Anti-Inflammatory Agents Phase 4
44 Anti-HIV Agents Phase 4
45 Cytochrome P-450 CYP3A Inhibitors Phase 4
protease inhibitors Phase 4
47 Anthelmintics Phase 4
48 HIV Protease Inhibitors Phase 4
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4
50 Anti-Infective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 264)
# Name Status NCT ID Phase Drugs
1 Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
2 Use Of High Dose Colistin in Multi Drug Resistant Gram Negative Infections in Critically Ill Adult Patients. Randomized Controlled Clinical Trial Unknown status NCT02162966 Phase 4 High Dose Colistin;Standard Dose Colistin
3 Effect of Administration of 3rd Generation Cephalosporin (Ceftriaxone Versus Cefotaxime) on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (EB C3G-R) Unknown status NCT03922919 Phase 4 Cefotaxime Injection;Cefotaxime/ceftriaxone
4 Non-specific Effects of Rabies Vaccine on the Incidence of Common Infectious Disease Episodes: a Randomized Controlled Trial Unknown status NCT03656198 Phase 4 Sterile Water Injection
5 Effect of Chlorhexidine Skin Cleansing on Skin Flora of Newborn Infants in Bangladesh Completed NCT00198679 Phase 4 Chlorhexidine
6 Population Pharmacokinetics Analysis of Ethambutol in Overweight and Obese Volunteers Completed NCT01048697 Phase 4 Ethambutol
7 Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center for Adults Aged 65 Years or Older or Those With Defined Risk Factors for Invasive Pneumococcal Disease Completed NCT01944462 Phase 4
8 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
9 IGHID (Institute for Global Health and Infectious Diseases) 11911 - Cross-reactive N. Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine Completed NCT04094883 Phase 4
10 Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion Completed NCT01198925 Phase 4 piperacillin continuous infusion;piperacillin extended infusion
11 Comparison of the Immunogenicity of the 3+1 Schedule and the 2+1 Schedule of 7-valent Pneumococcal Conjugated Vaccine in Young Chinese Infants Completed NCT02040402 Phase 4
12 The Use of the Probiotic, Lactobacillus Rhamnosus GG to Evaluate Colonization With Antimicrobial Resistant Bacteria in High Risk Patients Completed NCT01551186 Phase 4
13 Ceftriaxone as Home Intravenous Therapy for Deep-Seated Staphylococcal Infections, a Randomized Non-Inferiority Trial Recruiting NCT04141787 Phase 4 Ceftriaxone;Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)
14 A Randomized Multicenter Clinical Trial of a New Treatment for Primary Smear- Positive Pulmonary Tuberculosis With Interleukin-2 Recruiting NCT04766307 Phase 4 Interleukin-2
15 Hospital Avoidance Strategies for Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Recruiting NCT03372941 Phase 4 Dalbavancin
16 Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota of Healthy Volunteers: a Randomized Clinical Trail Recruiting NCT04084106 Phase 4 Phenoxymethylpenicillin;Amoxicillin;Amoxicillin-clavulanic acid
17 The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study Not yet recruiting NCT04286503 Phase 4 Carrimycin;lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate;basic treatment
18 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate Terminated NCT04351191 Phase 4 Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
19 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate Terminated NCT04346667 Phase 4 Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
20 Behavioral Drug and HIV Risk Reduction Counseling With MMT in China Completed NCT01389180 Phase 3
21 A Phase III Clinical Trial for a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children Completed NCT02285036 Phase 3
22 Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Compared to Triclosan 1% / Isopropyl Alcohol 70% Completed NCT01762904 Phase 3
23 Effect of a Follow on Formula With Lactobacillus Fermentum on the Incidence of Infections Completed NCT01215656 Phase 2, Phase 3
24 Comparative Study of 2% Chlorhexidine Gluconate in 70% Isopropyl Alcohol Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers Completed NCT01321125 Phase 3
25 A Prospective, Randomized, Open Label, Active Comparator, Multicenter, National Trial to Compare the Efficacy and Safety of Sequential IV/PO Moxifloxacin 400 mg Once Daily Versus IV Amoxicillin/Clavulanate 2,0/0,2 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanate 875/125 mg Every 8 Hours in the Treatment of Adult Subjects With Complicated Skin and Skin Structure Infections Completed NCT00828971 Phase 3 Avelox (Moxifloxacin, BAY12-8039);Amoxicilline/clavulanic
26 Comparative Study of 70% Isopropyl Alcohol Against 2% Chlorhexidine- 70% Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination Completed NCT01361997 Phase 3
27 A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious Diagnoses Completed NCT00761462 Phase 3 Ciprofloxacin;Non-quinolone antibiotic
28 Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia Groups Completed NCT01288378 Phase 3 caspofungin acetate
29 A Phase III Study to Assess Immunogenicity and Safety of 4th LBVH0101 Vaccination Compared With 4th Hiberix™ Vaccination in Healthy Toddlers Who Completed Primary Vaccination in LG-VHCL002 Study Completed NCT01251133 Phase 3
30 Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis Completed NCT02717871 Phase 3 Cefazolin in combination with either tobramycin or gentamicin;Cycloplegic agents (cyclopentolate 1% eye drops);Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin );Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)
31 A Multicentre, Comparative, Two-arm, Parallel-group, Double-blind, Randomized Phase III Study to Assess Immunogenicity and Safety of LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine) Compared With Hiberix™ Vaccine in Healthy Infants at Two, Four and Six Months of Age Completed NCT01019772 Phase 3
32 CSP #2004 - Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH) Recruiting NCT03005379 Phase 2, Phase 3 Fecal Microbiota Therapy (FMT);Placebo
33 Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Emerging Transfusion Transmitted Infections Recruiting NCT03737669 Phase 3
34 A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19) Recruiting NCT04558021 Phase 3 Niclosamide suspension
35 ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial) Recruiting NCT04352933 Phase 3 Hydroxychloroquine - Daily dosing;Hydroxychloroquine - Weekly Dosing
36 A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System Active, not recruiting NCT04435379 Phase 3
37 A Randomized, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) and Human Intravenous Anti COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. Not yet recruiting NCT04395170 Phase 2, Phase 3 Standard (specific) therapy for COVID-19
38 Impact of Colchicine in Hospitalized Colombian Patients With COVID-19 Not yet recruiting NCT04539873 Phase 3 Colchicine 0.5 MG
39 Phase III, Random-Open, Clinical Trials on the Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia Suspended NCT04613271 Phase 3 Favipiravir;Azithromycin
40 Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
41 A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB®, Both Co-administered With Prevnar 13® at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13® Unknown status NCT01732198 Phase 2
42 A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT) Completed NCT00285259 Phase 2
43 Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone Completed NCT01101815 Phase 2 Oral Naltrexone;Naltrexone Implant
44 A Phase II, Multi-Center, Double-Blind, Randomized Trial Comparing the Safety and Immunogenicity of a Francisella Tularensis Live Vaccine Strain (LVS) Vaccine Produced by DynPort Vaccine Company (DVC-LVS) to a LVS Vaccine in Use by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID-LVS) Completed NCT01150695 Phase 2
45 Incidence of Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics Lactobacillus Boucardii. Completed NCT02226263 Phase 2
46 Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19 Completed NCT04662671 Phase 1, Phase 2
47 A Modified Phase I/II Trial Of Rapamycin In Patients With Glioblastoma Multiforme Completed NCT00047073 Phase 1, Phase 2 Rapamycin
48 Fermented Milk on the Appearance of Common Winter Infectious Diseases Completed NCT02367612 Phase 2
49 Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment: Building Translational Research Capacity in Nutrition and Infectious Diseases in the Republic of Georgia Completed NCT00918086 Phase 2
50 The Effectiveness and Efficacy of Using JUC Antimicrobial Spray for Controlling the Infection Transmission Completed NCT01824888 Phase 2 JUC solution;propan-2-ol

Search NIH Clinical Center for Disease by Infectious Agent

Genetic Tests for Disease by Infectious Agent

Anatomical Context for Disease by Infectious Agent

MalaCards organs/tissues related to Disease by Infectious Agent:

Skin, Kidney, T Cells, Brain, Neutrophil, Myeloid, Breast

Publications for Disease by Infectious Agent

Articles related to Disease by Infectious Agent:

(show top 50) (show all 30167)
# Title Authors PMID Year
Facilitating Understanding, Modeling and Simulation of Infectious Disease Epidemics in the Age of COVID-19. 42 61
33643988 2021
Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland, Australia. 42
33632091 2021
Primary Cutaneous Diphtheria as a Rare Cause of Infectious Ulceration. 42
33637172 2020
High-throughput genotyping of mannose-binding lectin variants using high-resolution DNA-melting analysis. 61 54
20127985 2010
Integrated pathways for neutrophil recruitment and inflammation in leprosy. 54 61
20070238 2010
Mannan-binding lectin B allele is associated with a risk of developing more severe gastric mucosal atrophy in Helicobacter pylori-infected Japanese patients. 61 54
19352197 2009
Evaluation of iron deficiency as a nutritional adaptation to infectious disease: an evolutionary medicine perspective. 54 61
18949769 2009
NRAMP1 (SLC11A1) gene polymorphisms that correlate with autoimmune versus infectious disease susceptibility in tuberculosis and rheumatoid arthritis. 54 61
19055603 2009
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. 61 54
19133797 2009
Langerhans cells in porcine skin. 61 54
18805593 2008
[Evolution of IGRA researches]. 54 61
18979999 2008
An analytical workflow for investigating cytokine profiles. 54 61
18163472 2008
Persistent Coxiella burnetii infection in mice overexpressing IL-10: an efficient model for chronic Q fever pathogenesis. 61 54
18248094 2008
The Role of Mannan-Binding Lectin (MBL) Gene Polymorphism in Ulcerative Colitis. 54 61
18231631 2008
In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. 61 54
17893564 2007
Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. 54 61
17645779 2007
Innate immunity: toll-like receptors and some more. A brief history, basic organization and relevance for the human newborn. 61 54
17476116 2007
IFNG and IFNGR1 gene polymorphisms and susceptibility to post-kala-azar dermal leishmaniasis in Sudan. 54 61
17136124 2007
CJD: update for dental staff. 61 54
17087448 2006
Variable mannose-binding lectin expression during postoperative acute-phase response. 54 61
17083310 2006
Analysis of viral and genetic factors in South African patients with multiple sclerosis. 54 61
16865539 2006
Proteinase 3 expression on neutrophil membranes from patients with infectious disease. 54 61
16878019 2006
Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation. 61 54
16734634 2006
Involvement of chemokine receptors in organ-specific metastasis. 54 61
16627966 2006
Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. 61 54
16365416 2006
Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses. 61 54
16365436 2006
Regulation of drug metabolism and disposition during inflammation and infection. 54 61
16863429 2005
Studying human pathogens in animal models: fine tuning the humanized mouse. 54 61
16315087 2005
Mcl-1. 54 61
15474972 2005
LPS, TLR4 and infectious disease diversity. 61 54
15608698 2005
TNF/TNFR family members in costimulation of T cell responses. 61 54
15771565 2005
Clinical trials of deep vein thrombosis prophylaxis in medical patients. 54 61
16758648 2005
IL-10 gene polymorphisms in infectious disease and SIDS. 54 61
15325397 2004
Characterization of bovine homologues of granulysin and NK-lysin. 61 54
15294977 2004
Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. 61 54
14991068 2004
Association of Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa. 61 54
14740869 2003
Impact of mannose-binding lectin on susceptibility to infectious diseases. 61 54
14614673 2003
The role of mannose-binding lectin in health and disease. 54 61
14568388 2003
IRAK-4 as the central TIR signaling mediator in innate immunity. 54 61
12297423 2002
The roles of IFN gamma in protection against tumor development and cancer immunoediting. 54 61
11900986 2002
TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients. 61 54
11781708 2001
Genetics and genomics in infectious disease susceptibility. 61 54
11689339 2001
Pulp-dentin biology in restorative dentistry. Part 4: Dental caries--characteristics of lesions and pulpal reactions. 54 61
11695140 2001
Presence of IFN-gamma and IL-4 in human periapical granulation tissues and regeneration tissues. 61 54
11444909 2001
T-cell release of granulysin contributes to host defense in leprosy. 54 61
11175847 2001
Reduced IFN-gamma production in elderly people following in vitro stimulation with influenza vaccine and endotoxin. 61 54
11164467 2000
Ilodecakin. Schering-Plough Corp. 54 61
16118714 1999
Peripheral T lymphocyte cytokine profile (IFNgamma, IL-2, IL-4) and CD30 expression/release during measles infection. 61 54
10457402 1999
Nuvance (Immunex). 61 54
16155848 1999
Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. 61 54
10227396 1999

Variations for Disease by Infectious Agent

Expression for Disease by Infectious Agent

Search GEO for disease gene expression data for Disease by Infectious Agent.

Pathways for Disease by Infectious Agent

Pathways related to Disease by Infectious Agent according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.38 TLR9 TLR7 TLR4 TLR2 IL18 IL17A
Show member pathways
13.21 TLR9 TLR7 TLR4 TLR2 MBL2 IL18
Show member pathways
Show member pathways
12.69 TLR9 TLR7 TLR4 TLR2 IL18
Show member pathways
12.61 TLR9 TLR4 TLR2 IL17A IL10 IFNGR1
Show member pathways
Show member pathways
12.59 TLR4 TLR2 IL18 IL17A IL10 IFNGR1
9 12.58 TLR9 TLR7 TLR2 IL17A IL10 IFNG
Show member pathways
Show member pathways
12.23 TLR9 TLR7 TLR4 TLR2
Show member pathways
Show member pathways
15 12.12 TLR4 TLR2 MBL2 CD209
Show member pathways
12.02 TLR9 TLR7 TLR4 TLR2
17 11.98 IL10 IFNG CD209 CD1C
18 11.95 TLR4 TLR2 IL10 IFNG CD1C
19 11.9 TLR4 TLR2 IL18 IL17A IFNG
20 11.83 TLR9 TLR7 TLR4 TLR2
21 11.81 TLR9 TLR4 TLR2 IL18 IL10 IFNGR1
22 11.8 IL18 IL17A IL10 IFNG CCR6
Show member pathways
24 11.67 TLR9 TLR7 IL10 IFNG CD209 CD1C
25 11.58 TLR4 TLR2 IL18
26 11.56 TLR4 TLR2 IL18 IFNG
27 11.55 TLR9 TLR4 TLR2 IL10 ICOSLG CCR6
28 11.44 TLR9 IL18 IL10 IFNG
29 11.33 TLR9 TLR4 TLR2 IL18 IL10 IFNG
30 11.3 IL18 IL17A IFNG
31 11.18 TLR2 IL18 IFNG
Show member pathways
11.16 TLR9 TLR7 TLR4 TLR2 IL18 IL17A

GO Terms for Disease by Infectious Agent

Cellular components related to Disease by Infectious Agent according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 SERPINA3 MIR21 MIR155 MIR122 MBL2 IL18
2 endosome membrane GO:0010008 9.55 TLR9 TLR7 TLR4 SLC11A1 CD1C
3 early phagosome GO:0032009 9.26 TLR9 TLR7
4 external side of plasma membrane GO:0009897 9.1 TLR4 IL17A ICOSLG CD209 CD1C CCR6

Biological processes related to Disease by Infectious Agent according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 TLR9 TLR7 TLR4 TLR2 IL18 IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 TLR9 TLR4 TLR2 SLC11A1 IL18 IL17A
3 immune system process GO:0002376 10.18 TLR9 TLR7 TLR4 TLR2 MBL2 IL17A
4 innate immune response GO:0045087 10.17 TLR9 TLR7 TLR4 TLR2 MBL2 IL17A
5 adaptive immune response GO:0002250 10.11 IL17A IFNG ICOSLG CD209 CD1C
6 inflammatory response GO:0006954 10.06 TLR9 TLR7 TLR4 TLR2 SLC11A1 SERPINA3
7 defense response to bacterium GO:0042742 10.05 TLR9 TLR4 SLC11A1 MIR155 MBL2 IL10
8 response to lipopolysaccharide GO:0032496 10.02 TLR4 TLR2 SLC11A1 MIR155 IL10
9 defense response to virus GO:0051607 10 TLR9 TLR7 MIR155 IFNG
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TLR9 TLR4 TLR2 IL18
11 defense response to Gram-negative bacterium GO:0050829 9.94 TLR9 TLR4 SLC11A1 IL17A
12 negative regulation of interleukin-6 production GO:0032715 9.93 TLR9 TLR4 MIR155 IL10
13 positive regulation of interleukin-8 production GO:0032757 9.91 TLR9 TLR7 TLR4 TLR2
14 positive regulation of cytokine production GO:0001819 9.91 SLC11A1 MIR21 IL10 IFNG
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TLR9 TLR7 TLR4 TLR2 IL18
16 positive regulation of gene expression GO:0010628 9.91 TLR9 TLR4 TLR2 SLC11A1 MIR21 MIR155
17 positive regulation of interferon-gamma production GO:0032729 9.89 TLR9 TLR7 TLR4 SLC11A1 IL18
18 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.88 TLR9 TLR7 TLR4
19 toll-like receptor signaling pathway GO:0002224 9.88 TLR9 TLR7 TLR4 TLR2
20 positive regulation of interleukin-1 beta production GO:0032731 9.87 TLR4 IL17A IFNG
21 positive regulation of interferon-beta production GO:0032728 9.87 TLR9 TLR7 TLR4 TLR2
22 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.86 TLR9 TLR7 TLR4 TLR2
23 negative regulation of interleukin-8 production GO:0032717 9.85 TLR9 MIR155 IL10
24 positive regulation of interleukin-10 production GO:0032733 9.85 TLR9 TLR4 TLR2
25 microglial cell activation GO:0001774 9.85 TLR7 TLR2 IFNGR1 IFNG
26 positive regulation of interleukin-6 production GO:0032755 9.85 TLR9 TLR7 TLR4 TLR2 IL17A IFNG
27 negative regulation of cytokine production GO:0001818 9.84 SLC11A1 MIR155 IL10
28 positive regulation of activated T cell proliferation GO:0042104 9.84 MIR21 MIR155 IL18 ICOSLG
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TLR4 TLR2 IL18
30 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.82 TLR4 MIR21 IL17A
31 positive regulation of interferon-alpha production GO:0032727 9.82 TLR9 TLR7 TLR4
32 positive regulation of macrophage activation GO:0043032 9.81 TLR4 MIR155 IL10
33 positive regulation of chemokine production GO:0032722 9.8 TLR9 TLR7 TLR4 TLR2 IFNG
34 positive regulation of tumor necrosis factor production GO:0032760 9.8 TLR9 TLR4 TLR2 IL17A IFNGR1 IFNG
35 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.78 TLR9 TLR4 TLR2 IFNG
36 positive regulation of MHC class II biosynthetic process GO:0045348 9.77 TLR4 IL10 IFNG
37 response to molecule of bacterial origin GO:0002237 9.77 TLR9 TLR2 IL10
38 I-kappaB phosphorylation GO:0007252 9.73 TLR9 TLR7 TLR4 TLR2
39 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.72 TLR4 MIR155
40 negative regulation of amyloid-beta clearance GO:1900222 9.72 IFNGR1 IFNG
41 cellular response to lipoteichoic acid GO:0071223 9.71 TLR4 TLR2
42 T-helper 1 type immune response GO:0042088 9.71 TLR4 IL18
43 regulation of cytokine secretion GO:0050707 9.71 TLR9 TLR2
44 negative regulation of regulatory T cell differentiation GO:0045590 9.71 MIR21 MIR155
45 immune response GO:0006955 9.7 TLR9 TLR7 TLR4 TLR2 SLC11A1 IL18
46 intestinal epithelial structure maintenance GO:0060729 9.69 TLR4 IL17A
47 type 2 immune response GO:0042092 9.69 IL18 IL10
48 positive regulation of interleukin-23 production GO:0032747 9.68 IL17A IFNG
49 positive regulation of interleukin-18 production GO:0032741 9.68 TLR9 TLR2
50 positive regulation of toll-like receptor signaling pathway GO:0034123 9.67 TLR9 TLR2

Molecular functions related to Disease by Infectious Agent according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.67 TLR9 TLR7 TLR4 TLR2
2 cytokine activity GO:0005125 9.56 IL18 IL17A IL10 IFNG
3 siRNA binding GO:0035197 9.32 TLR9 TLR7
4 lipopeptide binding GO:0071723 9.16 TLR2 CD1C
5 lipopolysaccharide receptor activity GO:0001875 8.96 TLR4 TLR2
6 pattern recognition receptor activity GO:0038187 8.8 TLR9 TLR7 TLR2

Sources for Disease by Infectious Agent

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....